BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of BOSULIF (bosutinib) tablets brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the BOSULIF (bosutinib) tablets tablets cost price in India.
The order for BOSULIF (bosutinib) tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Bosutinib (codenamed SKI-606, marketed under the trade name Bosulif) is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
BOSULIF (bosutinib) tablets tablets, for oral use.
Generic Name: bosutinib
Tablets: 100 mg and 500 mg. (
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand BOSULIF (bosutinib) tablets on prescription and Import License in Patient's Name only.
For overseas patients, BOSULIF (bosutinib) tablets can be made available in Send your enquiry to find BOSULIF (bosutinib) tablets in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For BOSULIF (bosutinib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML) For More Details
U.S. FDA APPROVES PFIZER’S BOSULIF® (BOSUTINIB) FOR THE TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) For More Details